A Phase 1 trial reports that the oral drug TLC-2716 cuts triglycerides by 38% and remnant cholesterol by 61%. By inhibiting the LXR protein specifically in the liver and gut, the drug successfully lowers blood fats without disrupting vital protective cholesterol pathways found elsewhere in the body.
Published 2 hours ago
Source: reddit.com
Categories
science
Related Articles from reddit.com
58 minutes ago
Terror attacks make people overestimate the share of Muslims in the country, with largest effect among low-educated and in low-immigrant regions, new study finds
1 hour ago
A staph aureus protein is engineered to target and deliver toxins into cancer cells
1 hour ago
‘We could hit a wall’: why trillions of dollars of risk is no guarantee of AI reward
1 hour ago
Trump says he may punish countries with tariffs if they don’t back the US controlling Greenland
2 hours ago
Wikipedia is now getting paid by Meta, Microsoft, Perplexity, and other AI companies
2 hours ago